MedTrace Logo

Effect of Beta-Glucan on Cholesterol Lowering

NCT01408719 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2015-11-05

Study results available
· View outcomes & findings →

Summary

The primary aim of this study is to determine whether the cholesterol-lowering efficacy of barley b- glucan varied as function of molecular weight (MW) and the total daily amount consumed. Our second aim is to investigate the mechanism responsible for the action, specifically, whether β-glucan lowers circulating cholesterol concentration via inhibiting cholesterol absorption and synthesis. Thirdly, we aim to determine if any gene-diet interactions are associated with cholesterol lowering by barley β-glucan. In addition, we aim to investigate the alteration of the gut microbiota after β-glucan consumption and the correlation between the altered gut microbiota and cardiovascular disease risk factors.

Conditions

Interventions

DIETARY_SUPPLEMENT

Control

Minimal beta-glucan

DIETARY_SUPPLEMENT

3g LMW beta-glucan

3grams beta-glucan

DIETARY_SUPPLEMENT

5g LMW beta-glucan

5 grams beta-glucan

DIETARY_SUPPLEMENT

3g HMW beta-glucan

3 grams of high molecular weight beta-glucan

Sponsors & Collaborators

  • Agriculture and Agri-Food Canada

    collaborator OTHER_GOV

  • University of Manitoba

    lead OTHER

Principal Investigators

  • Nancy Ames, PhD · AAFC

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
78 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2012-02-29
Completion
2012-02-29

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01408719 on ClinicalTrials.gov